Investor Presentaiton
National reimbursement in Japan & lab launch in
China taps into large global market
Japan
Potential for rapid growth: 1M new cancer cases per year¹, centralized care,
<10% penetration of CGP market²
Driving business: National reimbursement approval from the Japanese MHLW
for Guardant360 CDx + efficient local sales model + strong ASP
China
Point of differentiation: China is a critical, strategic market for biopharma
partnerships
Strategic partnership for growth: 30+ biopharma clients have engaged
with Guardant since partnership with Adicon lab
INVESTOR 20
DAY 23
GUARDANT
93
1.International Agency for Research on Cancer. Japan. Globocan 2020. https://gco.iarc.fr/toaday/data/factsheets/populations/392-japan-fact-sheets.pdf 2. Japan C-CAT databaseView entire presentation